Rocket Pharmaceuticals Inc., of New York, reported preclinical data from its leukocyte adhesion deficiency-1 (LAD-1) and infantile malignant osteopetrosis lentiviral vector (LVV)-based gene therapy programs at the European Society of Gene and Cell Therapy meeting in Lausanne, Switzerland.